AnaptysBio Inc
$ 43.76
6.99%
03 Dec - close price
- Market Cap 1,224,098,000 USD
- Current Price $ 43.76
- High / Low $ 44.28 / 40.52
- Stock P/E N/A
- Book Value -1.07
- EPS -2.82
- Next Earning Report 2026-03-09
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -3.08 %
- 52 Week High 44.28
- 52 Week Low 12.21
About
AnaptysBio, Inc. is a clinical-stage biotechnology company based in San Diego, California, focused on developing cutting-edge therapeutics targeting inflammatory diseases and immuno-oncology. Leveraging its proprietary antibody development platforms, the company is advancing a diverse pipeline of candidates through clinical trials, aiming to address significant unmet medical needs across various therapeutic areas. With a strong emphasis on scientific innovation and a commitment to delivering transformative therapies, AnaptysBio presents a compelling investment opportunity for institutional investors seeking high-growth potential in the biotechnology landscape.
Analyst Target Price
$63.91
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-07 | 2025-05-07 | 2025-03-10 | 2024-11-08 | 2024-08-05 | 2024-05-09 | 2024-03-11 | 2023-11-02 | 2023-08-07 | 2023-05-11 | 2023-03-01 |
| Reported EPS | 0.52 | -1.34 | -1.28 | -0.72 | -1.14 | -1.71 | -1.64 | -1.59 | -1.41 | -1.5 | -1.58 | -0.93 |
| Estimated EPS | -1.4 | -1.52 | -1.56 | -1.7049 | -1.65 | -0.99 | -1.57 | -1.6 | -1.79 | -1.7 | -1.05 | -0.96 |
| Surprise | 1.92 | 0.18 | 0.28 | 0.9849 | 0.51 | -0.72 | -0.07 | 0.01 | 0.38 | 0.2 | -0.53 | 0.03 |
| Surprise Percentage | 137.1429% | 11.8421% | 17.9487% | 57.7688% | 30.9091% | -72.7273% | -4.4586% | 0.625% | 21.2291% | 11.7647% | -50.4762% | 3.125% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-09 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.614 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ANAB
2025-11-02 11:40:40
This page provides the latest news and market updates for Anaptysbio Inc. (ANAB), a clinical-stage biotechnology company focused on antibody therapies for autoimmune and inflammatory diseases. It includes recent clinical trial results for rosnilimab in rheumatoid arthritis, financial reports, investor events, and the company's plan to separate its biopharma operations from its royalty assets by year-end 2026.
2025-10-31 00:32:04
AnaptysBio announced positive Phase 2b trial results for rosnilimab in rheumatoid arthritis, demonstrating significant and durable clinical improvements with a favorable safety profile. The drug showed deepening clinical responses and was well-tolerated with no serious adverse events or malignancies reported through Week 38. These findings suggest rosnilimab could be a promising new treatment option, particularly for patients who have not responded to existing therapies.
2025-10-17 19:24:25
AnaptysBio, Inc. saw a significant intraday surge of 7.66%, reaching a day high of USD 34.41 on October 15, 2025. While the company has shown impressive short-term gains and year-to-date resilience (158.99% increase), it faces challenges including operating losses and weak long-term financial strength with a negative EBIT to Interest ratio of -10.25. The company's market capitalization stands at USD 621 million, as it navigates a complex industry landscape.
2025-10-17 10:38:05
Wedbush has increased its FY2025 earnings per share estimates for AnaptysBio, upgrading their forecast from ($4.27) to ($1.86) per share, maintaining an "Outperform" rating and a $70.00 price objective. Other firms like Barclays and JPMorgan Chase & Co. also issued positive ratings and increased price targets. AnaptysBio recently topped Q2 earnings estimates, reporting ($1.34) EPS versus an expected ($1.50) and revenue of $22.26 million against expectations of $11.55 million.
2025-10-16 14:24:02
Stock Traders Daily's AI models indicate strong sentiment for Anaptysbio Inc. (NASDAQ: ANAB) across all time horizons, suggesting an overweight bias with a breakout underway. The analysis provides specific trading strategies (Position Trading, Momentum Breakout, Risk Hedging) with entry zones, targets, and stop losses. Despite strong signals, elevated downside risk is noted due to a lack of additional long-term support signals.
2025-10-15 15:38:55
Wedbush has reaffirmed an "Outperform" rating for AnaptysBio (ANAB) and significantly increased its price target from $45.00 to $70.00, a 55.56% jump. This follows a trend of positive analyst adjustments, with Barclays initiating coverage with an "Overweight" rating and HC Wainwright & Co. also raising its price target. Analysts' collective sentiment signals a bullish outlook for AnaptysBio, a clinical-stage biotechnology company focused on inflammation and immuno-oncology, with an average target price implying a 65.47% upside.
